Quince Therapeutics, Inc. QNCX 深 滬
等待開盤 06-12 09:30:00 美东时间
0.947
+0.037
+4.07%
華盛通- 最 高0.9608
- 今 開0.92
- 成交量 37.07万股
- 最 低 0.89
- 昨 收 0.91
- 總市值 1852.26万
- 52周最高 45.499
- 市盈率 靜 --
- 換手率 1.90%
- 52周最低 0.79
- 委 比 -88.59%
- 總股本 1955.93万
- 歷史最高 1219.80
- 量 比 0.58
- 振 幅 7.78%
- 歷史最低 0.80
- 每 手 1
- 風險率 11.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Quince Therapeutics Stockholders Approve Reverse Split Authorization
Quince Therapeutics ( ($QNCX) ) has provided an update. On June 11, 2026, Quinc...
今天 06:42
Quince Therapeutics Announces Acquisition Of Orphai Therapeutics In Stock-For-Stock Deal; Quince Enters Concurrent Private Placement Agreement To Raise Up To $187M
The acquisition is structured as a stock-for-stock merger, pursuant to which all outstanding equity interests of Orphai will be exchanged based on a fixed exchange ratio for a combination of 3,258,517 shares common
05-18 21:33
Quince Therapeutics Reports Phase 2a Data For LAM-001 In Pulmonary Hypertension-Associated ILD, Demonstrated Clinically Meaningful Improvement In Multiple Assessments Of Lung Function, Including Improvement In 6MWD Of 67.4 Meters And PVR Reduction Of 33.9% At 24 Weeks; Phase 2b Trial In PH-ILD To Initiate In Mid-2026, With Topline Data Anticipated In Q1 2028
Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD
05-18 21:31
Quince Therapeutics Appoints June Bray to Board
Quince Therapeutics ( ($QNCX) ) has shared an update. On April 22, 2026, Quince...
04-23 05:33
Why Levi Strauss Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Levi Strauss (LEVI) reported strong Q1 2026 results, raising revenue & earnings guidance. Other pre-market gainers include QNCX, VSME, UCAR, IPW, JEM, AZI, GPUS, AXTI, IPX.
04-08 17:33
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Lunai Bioworks (NASDAQ:LNAI) stock moved upwards by 47.2% to $0.41 dur...
04-08 01:05
Quince Therapeutics Eliminates EIB Debt, Boosts Flexibility
Quince Therapeutics ( ($QNCX) ) has provided an update. On March 27, 2026, Quin...
03-30 22:23
BRIEF-Quince Therapeutics Settles Approximately $16.4 Million Of Debt
BRIEF-Quince Therapeutics Settles Approximately $16.4 Million Of Debt March 30 (Reuters) - Quince Therapeutics Inc QNCX.O : QUINCE THERAPEUTICS SETTLES APPROXIMATELY $16.4 MILLION OF DEBT Source text: ID:nBw9dLCyra Further company coverage: QNCX.O (( Reuters.Briefs@thomsonreuters.com ;))
03-30 22:09
Quince Therapeutics clears $16M EIB debt; shares surge 18%
Quince Therapeutics (QNCX) settled its outstanding ~$16.4M EIB loan at a discounted payoff of $5.5M, reducing its debt balance sheet. CEO & CMO Dirk Thye said the company had settled its EIB debt to a...
03-30 21:45
Quince Therapeutics settles $16M EIB debt for $5.5M payment
Quince Therapeutics settles $16M EIB debt for $5.5M payment Quince Therapeutics settled about $16 million of outstanding European Investment Bank debt via a $5.5 million payment. Obligations under both settlement agreement and underlying loan agreement were fully satisfied and discharged effective i
03-30 20:36
